CD37 immunotherapeutics and uses thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 18, 2012
Grant Date -
Jul 14, 2011
app pub date -
Apr 11, 2009
filing date -
Apr 11, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully